Clinical Trial Update: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating intravenous Ravulizumab for prevention of delayed graft function in adults after kidney transplantation; the study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Delayed Graft Function, DGF | Phase 3 | Status: RECRUITING